Table 1.
Participant-level characteristics by study.
| Study | ITT N | Treatment | Comparator | Age | % Female | % Racial/Ethnic Minority | % Met PTSD Diagnostic Criteria | % Met SUD Diagnostic Criteria | % with Current Drug Use |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Back et al. (2019) | 81 | ITF | Manual SUD | 40.4 | 9.9 | 39.5 | 100 | 100 | 37.1 |
| Boden et al. (2011) | 98 | NTF | TAU | 54 | 0 | 81 | NA | 100 | 80.6 |
| Brief PC | 386 | NTF | No/minimal tx | 32.15 | 13.40 | 22.25 | NA | NA | NA |
| Capone et al. (2014) | 44 | NTF | TAU | 34.29 | 4.55 | 15.85 | 100 | 100 | 38.6 |
| Coffey et al. (2016) | 126 | TF | TAU1 | 34 | 46 | 20.6 | 100 | 100 | NA |
| van Dam, Ehring, Vedel, and Emmelkamp (2013) | 34 | TF | Manual SUD | 42.3 | 32.4 | 26.5 | 61.8 | 100 | 55.9 |
| Foa et al. (2013) | 165 | TF (+Nal) | Manual SUD | 42.7 | 34.5 | 69.7 | 100 | 100 | NA |
| TF (+PL) | Manual SUD | ||||||||
| Haller PC | 101 | ITF | TAU2 | 46.4 | 10.9 | 37.6 | 100 | 100 | 58.5 |
| Hamblen (2020) | 129 | TF | TAU | 44.2 | 5.4 | 32.8 | 100 | 100 | 92 |
| Hien, Cohen, Miele, Litt, and Capstick (2004) | 75 | NTF | Manual SUD | 36 | 100 | 36 | 88 | 100 | 65.3 |
| Hien et al. (2009) | 353 | NTF | TAU1 | 39.2 | 100 | 54.4 | 80.4 | 100 | 91.2 |
| Kehle-Forbes et al. (2018)3 | 183 | ITF | TF | 44.1 | 7.75 | 58.95 | 100 | 100 | 18 |
| McGovern, Lambert-Harris, Alterman, Xie, and Meier (2011) | 53 | NTF | Manual SUD | 37.3 | 56.6 | 8.7 | 100 | 100 | 47.2 |
| McGovern et al. (2015) | 221 | NTF | Manual SUD | 35.3 | 59.3 | 4.5 | 100 | 100 | 51.1 |
| Mills et al. (2012) | 103 | ITF | No/minimal tx | 33 | 62.1 | 5.8 | 100 | 100 | 79.6 |
| Myers, Browne, and Norman (2015) | 40 | NTF | Manual SUD | 42.2 | 100 | 48.4 | 80.6 | 100 | NA |
| Najavits et al. (2018) 3 | 52 | ITF | NTF | 48.7 | 26.9 | 40 | 100 | 100 | 50 |
| Norman et al. (2019) 3 | 119 | ITF | NTF | 41.6 | 10.1 | 34.5 | 95.8 | 100 | NA |
| Perez-Dandieu and Tapia (2014) | 12 | TF | TAU | 29.5 | 100 | NA | 100 | 100 | 83.3 |
| Possemato et al. (2019) 3 | 30 | NTF | NTF | 38.6 | 6.7 | 20 | 76.7 | 100 | NA |
| Ruglass et al. (2017) | 110 | ITF | Manual SUD | 44.4 | 36.4 | 81.8 | 64.5 | 98.2 | 66.4 |
| Sannibale et al. (2013) | 62 | ITF | Manual SUD | 41.2 | 53 | NA | 100 | 95 | 15 |
| Schacht et al. (2017) 3 | 58 | TF | TF | 37.4 | 79 | 29 | 100 | 100 | 100 |
| Schafer et al. (2019) | 343 | NTF | Manual SUD | 40.97 | 100 | 9.6 | NA | 100 | NA |
| Simpson et al. (2021) 4 | 101 | TF | Manual SUD | 42.1 | 56 | 47 | 100 | 100 | 38.6 |
| Stappenbeck et al. (2015) | 78 | NTF | No/minimal tx | 44.3 | 48.7 | 57.7 | 100 | 100 | NA |
| Vujanovic, Smith, Tipton, and Schmitz (2018) 4 | 41 | ITF | Manual SUD | 44.9 | 53.7 | 75.6 | NA | 100 | NA |
| Zlotnick, Johnson, and Najavits (2009) | 49 | NTF | TAU | 34.6 | 100 | 53.1 | 83.5 | 100 | NA |
Note: ITT N = intention-to-treat sample size; NA = not available; PC = Personal Communication; Manual SUD = manualized SUD treatment; No tx = no/minimal treatment; TAU = SUD TAU; NA = information not collected/reported; NTF = not trauma-focused; TF = trauma-focused; ITF = integrated trauma-focused; NAL = Naloxone; PL = placebo drug.
Participants received SUD TAU and a general healthy lifestyle or health-oriented attention placebo control.
Participants received an integrated CBT intervention to address depression and SUD.
Studies that did not contribute to between-group analyses.
Unpublished studies at time analyses undertaken.